PMID- 38541574
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 1996-1944 (Print)
IS  - 1996-1944 (Electronic)
IS  - 1996-1944 (Linking)
VI  - 17
IP  - 6
DP  - 2024 Mar 20
TI  - Development of a Resveratrol Nanoformulation for the Treatment of Diabetic 
      Retinopathy.
LID - 10.3390/ma17061420 [doi]
LID - 1420
AB  - Diabetic retinopathy (RD) is a microvascular disease that can cause the formation 
      of fragile neovessels, increasing the risk of hemorrhages and leading to vision 
      loss. Current therapies are based on the intravitreal injection of anti-VEGF 
      (vascular endothelial growth factor), which is invasive and can cause secondary 
      effects. The development of new treatments that complement the current therapies 
      is necessary to improve the patient's outcomes. Nanostructured formulations offer 
      several advantages regarding drug delivery and penetration. In this research, a 
      resveratrol nanosuspension (RSV-NS) was prepared and characterized using dynamic 
      light scattering, field emission scanning electron microscopy, and infrared 
      spectroscopy. The RSV-NS had an average particle size of 304.0 +/- 81.21 nm with a 
      PDI of 0.225 +/- 0.036, and a spherical-like morphology and uniform particle 
      distribution. Cell viability, proliferation, and migration were tested on 
      endothelial cells (HMRECs). RSV-NS in a concentration of less than 18.75 microM did 
      not have a cytotoxic effect on HMRECs. Likewise, proliferation and migration were 
      significantly reduced compared to the unstimulated control at 37.5 microM. The RSV-NS 
      did not present cytotoxic effects but decreased cell proliferation and migration, 
      indicating that it could provide an important contribution to future medical 
      implementations and could have a high potential to treat this disease.
FAU - Gonzalez-Perez, Juliana
AU  - Gonzalez-Perez J
AUID- ORCID: 0000-0001-8146-5106
AD  - Grupo de Investigacion en Ingenieria Biomedica (GIBEC), Universidad EIA, Envigado 
      055428, Colombia.
AD  - Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA 02114, 
      USA.
FAU - Lopera-Echavarria, A M
AU  - Lopera-Echavarria AM
AUID- ORCID: 0000-0003-1368-1784
AD  - Grupo de Investigacion en Ingenieria Biomedica (GIBEC), Universidad EIA, Envigado 
      055428, Colombia.
FAU - Arevalo-Alquichire, Said
AU  - Arevalo-Alquichire S
AD  - Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA 02114, 
      USA.
AD  - Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
FAU - Araque-Marin, Pedronel
AU  - Araque-Marin P
AD  - Grupo de Investigacion en Ciencias Medicas, Universidad EIA, Envigado 055428, 
      Colombia.
FAU - Londono, Martha E
AU  - Londono ME
AUID- ORCID: 0000-0003-0576-4854
AD  - Grupo de Investigacion en Ingenieria Biomedica (GIBEC), Universidad EIA, Envigado 
      055428, Colombia.
LA  - eng
GR  - 133384468146/Ministerio de Ciencia, Tecnologia e Innovacion/
PT  - Journal Article
DEP - 20240320
PL  - Switzerland
TA  - Materials (Basel)
JT  - Materials (Basel, Switzerland)
JID - 101555929
PMC - PMC10972098
OTO - NOTNLM
OT  - cell migration
OT  - cell proliferation
OT  - cell viability
OT  - diabetic retinopathy
OT  - nanosuspension
OT  - resveratrol
COIS- The authors declare no conflicts of interest.
EDAT- 2024/03/28 06:44
MHDA- 2024/03/28 06:45
PMCR- 2024/03/20
CRDT- 2024/03/28 01:14
PHST- 2024/02/09 00:00 [received]
PHST- 2024/02/28 00:00 [revised]
PHST- 2024/03/05 00:00 [accepted]
PHST- 2024/03/28 06:45 [medline]
PHST- 2024/03/28 06:44 [pubmed]
PHST- 2024/03/28 01:14 [entrez]
PHST- 2024/03/20 00:00 [pmc-release]
AID - ma17061420 [pii]
AID - materials-17-01420 [pii]
AID - 10.3390/ma17061420 [doi]
PST - epublish
SO  - Materials (Basel). 2024 Mar 20;17(6):1420. doi: 10.3390/ma17061420.